

DAFTAR PUSTAKA

1. Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, et al. Comprehensive review of current management guidelines of chronic kidney disease. *Medicine (Baltimore)*. 2023;102(23):e33984.
2. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2020;395(10225):709–33.
3. Kementerian Kesehatan Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). 2018.
4. Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. *Adv Ther*. 2022;39(1):33–43.
5. Afiatin, Suhaimi N, Puspitasari M. 13th Annual Report Of Indonesian Renal Registry 2020. 2023.
6. Whaley-Connell A, Nistala R, Chaudhary K. The importance of early identification of chronic kidney disease. *Mo Med*. 2011;108(1):25-8.
7. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease. *Circulation*. 2021;143(11):1157–72.
8. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management. *JAMA*. 2019;322(13):1294.
9. Wouk N. End-Stage Renal Disease: Medical Management. *Am Fam Physician*. 2021;104(5):493–99.

10. Sunariyanti E, Andayani TM, Endarti D, Puspandari DA. Cost Analysis of Chronic Kidney Disease Patients in Indonesia. *ClinicoEconomics and Outcomes Research*. 2023;15: 621–9.
11. Eknayan G, Lameire N. KDIGO 2023 Clinical Practice Guideline for The Evaluation and Management of Chronic Kidney Disease. *Kidney Disease Improving Global Outcomes (KDIGO)*. 2023;1–339.
12. Velde M, Astor B, Woodward M, Levey A. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *The Lancet*. 2010;375(9731):2073–81.
13. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. *Arthritis Care Res*. 2011;63(6):865–74.
14. Yamanouchi M, Hoshino J, Ubara Y, Takaichi K, Kinowaki K, Fujii T, et al. Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. *Nephrology Dialysis Transplantation*. 2019;34(7):1182–8.
15. Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. *Adv Clin Chem*. 2015;68:57–69.
16. Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. *J Korean Med Sci*. 2011;26(2):258–63.

17. M. G. Shlipak, R. Katz, M. J. Sarnak. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. *Annals of Internal Medicine*. 2006; 145(4) 237–46.
18. Pivin E, Ponte B, de Seigneux S, Ackermann D, Guessous I, Ehret G, et al. Uromodulin and Nephron Mass. *Clinical Journal of the American Society of Nephrology*. 2018;13(10):1556–7.
19. Youhanna S, Weber J, Beaujean V, Glaudemans B, Sobek J, Devuyst O. Determination of uromodulin in human urine: influence of storage and processing. *Nephrology Dialysis Transplantation*. 2014;29(1):136–45.
20. Steubl D, Buzkova P, Ix JH, Devarajan P, Bennett MR, Chaves PHM, et al. Association of serum and urinary uromodulin and their correlates in older adults—The Cardiovascular Health Study. *Nephrology*. 2020;25(7):522–6.
21. Lv L, Wang J, Gao B, Wu L, Wang F, Cui Z, et al. Serum uromodulin and progression of kidney disease in patients with chronic kidney disease. *J Transl Med*. 2018;16(1):316.
22. Scherberich JE, Gruber R, Nockher WA, Christensen EI, Schmitt H, Herbst V, et al. Serum uromodulin—a marker of kidney function and renal parenchymal integrity. *Nephrology Dialysis Transplantation*. 2018;33(2):284–95.
23. Fedak D, Kuźniewski M, Fugiel A, Wieczorek-Surdacka E, Przepiórkowska-Hoyer B, Jasik P, et al. Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. *Pol Arch Intern Med*. 2016; 126(12):995–1004.

24. Steubl D, Block M, Herbst V, Nockher WA, Schlumberger W, Satanovskij R, et al. Plasma Uromodulin Correlates With Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients. *Medicine*. 2016;95(10):e3011.
25. Vaidya S, Aeddula N. Chronic Kidney Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2025:1–9.
26. Murphree DD, Thelen SM. Chronic Kidney Disease in Primary Care. *The Journal of the American Board of Family Medicine*. 2010;23(4):542–50.
27. Hustrini NM, Susalit E, Lydia A, Marbun MBH, Syafiq M, Yassir, et al. The Etiology of Kidney Failure in Indonesia: A Multicenter Study in Tertiary-Care Centers in Jakarta. *Ann Glob Health*. 2023;89(1):36.
28. Betzler BK, Sultana R, He F, Tham YC, Lim CC, Wang YX, et al. Impact of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) GFR Estimating Equations on CKD Prevalence and Classification Among Asians. *Front Med (Lausanne)*. 2022;9:957437.
29. Schnaper HW, Hubchak SC, Runyan CE, Browne JA, Finer G, Liu X, et al. A conceptual framework for the molecular pathogenesis of progressive kidney disease. *Pediatric Nephrology*. 2010;25(11):2223–30.
30. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and declining kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis*. 2003;41(1):1–12.
31. Wymer DC, Wymer DTG. Imaging the Chronic Kidney Disease Patient. *Chronic Renal Disease*. Elsevier; 2020; 1321–31.

32. Meola M, Samoni S, Petrucci I. Imaging in Chronic Kidney Disease. *Contrib Nephrol.* 2016;188:69–80.
33. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. *Nat Rev Dis Primers.* 2017;3(1):17088.
34. Jesudason S, Forbes C. Chronic kidney disease (CKD) management in primary care. *Kidney Health Australia.* 2020.
35. Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. *Int J Mol Sci.* 2020;22(1):43.
36. Younes-Ibrahim MS, Younes-Ibrahim M. Biomarkers and kidney diseases: a brief narrative review. *J Lab Precis Med.* 2022;7:20.
37. Webster AC, Nagler E V, Morton RL, Masson P. Chronic Kidney Disease. *The Lancet.* 2017; 389(10075):1238–52.
38. Devuyst O, Olinger E, Rampoldi L. Uromodulin: from physiology to rare and complex kidney disorders. *Nat Rev Nephrol.* 2017;13(9):525–44.
39. Schaeffer C, Devuyst O, Rampoldi L. Uromodulin: Roles in Health and Disease. *Annu Rev Physiol.* 2021;83(1):477–501.
40. Takata T, Isomoto H. The Versatile Role of Uromodulin in Renal Homeostasis and its Relevance in Chronic Kidney Disease. *Internal Medicine.* 2023;1342–22.
41. Kipp A, Olinger E. What Does Uromodulin Do? *Clinical Journal of the American Society of Nephrology.* 2021;16(1):150–3.

42. Reindl J, Gröne H. J, Wolf G, Busch M. Uromodulin-related autosomal-dominant tubulointerstitial kidney disease—pathogenetic insights based on a case. *Clinical kidney journal*. 2019;12(2): 172–9.
43. Thielemans R, Speeckaert R, Delrue C, De Bruyne S, Oyaert M, Speeckaert MM. Unveiling the Hidden Power of Uromodulin: A Promising Potential Biomarker for Kidney Diseases. *Diagnostics*. 2023;13(19):3077.
44. Thornley C, Dawnay A, Cattell WR. Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. *Clin Sci*. 1985;68(5):529–35.
45. Onoe T, Yamada K, Mizushima I, Ito K, Kawakami T, Daimon S, et al. Hints to the diagnosis of uromodulin kidney disease. *Clin Kidney J*. 2016;9(1):69–75.
46. Li H, Kostel SA, Di Martino SE, Hashemi Gheinani A, Froehlich JW, Lee RS. Uromodulin Isolation and Its N -Glycosylation Analysis by Nano LC-MS/MS. *J Proteome Res*. 2021;20(5):2662–72.
47. Yang PC, Mahmood T. Western blot: Technique, theory, and trouble shooting. *N Am J Med Sci*. 2012;4(9):429.
48. Levitskaya ES, Batiushin MM, Gasanov MZ. Uromodulin-Biological Significance and Prospects for Clinical Use. *The Russian Archives of Internal Medicine*. 2023;13(1):5–13.
49. Pruijm M, Ponte B, Ackermann D, Paccaud F, Guessous I, Ehret G, et al. Associations of Urinary Uromodulin with Clinical Characteristics and

- Markers of Tubular Function in the General Population. *Clinical Journal of the American Society of Nephrology*. 2016;11(1):70–80.
50. Risch L, Lhotta K, Meier D, Medina-Escobar P, Nydegger UE, Risch M. The serum uromodulin level is associated with kidney function. *Clin Chem Lab Med*. 2014;52(12):1755-61.
 51. Leiherer A, Muendlein A, Saely CH, Brandtner EM, Geiger K, Fraunberger P, et al. The value of uromodulin as a new serum marker to predict decline in renal function. *J Hypertens*. 2018;36(1):110–18.
 52. Çuhadar S. Serum Cystatin C as a Biomarker. In: *Biomarkers in Kidney Disease*. Dordrecht: Springer Netherlands; 2015. p. 1–17.
 53. Papuga M V, Bukumirić Z, Ilinčić B, Mijović R, Šašić Ostojić T, Žeravica R. Serum Uromodulin, a Potential Biomarker of Tubulointerstitial Damage, Correlates Well with Measured GFR and ERPF in Patients with Obstructive Nephropathy. *Medicina (Kaunas)*. 2022;26;58(12):1729.
 54. Dumpatna R, Tristina N, Turbawaty D K, Tjandrawati A. Validity of Serum Uromodulin as Early Diagnosis Marker of Diabetic Nephropathy in T2DM. *Bandung Medical Journal*. 2021; 53(2):107–13.
 55. McMurray MD, Trivax JE, McCullough PA. Serum Cystatin C, Renal Filtration Function, and Left Ventricular Remodeling. *Circ Heart Fail*. 2009;2(2):86–9.
 56. Dahl H, Meyer K, Sandnes K, Welland NL, Arnesen I, Marti HP, et al. Cystatin C proteoforms in chronic kidney disease. *PLoS One*. 2023;18(2):e0269436

57. Yaswir R, Maiyesi A. Pemeriksaan Laboratorium Cystatin C Untuk Uji Fungsi Ginjal. *Jurnal Kesehatan Andalas*. 2012;1(1):1–4.
58. Pöge U, Gerhardt T, Bökenkamp A, Stoffel-Wagner B, Klehr HU, Sauerbruch T, et al. Time course of low molecular weight proteins in the early kidney transplantation period – influence of corticosteroids. *Nephrol Dial Transplant*. 2004;19:2858–63.
59. Porto JR, Gomes KB, Fernandes AP, Domingueti CP. "Cystatin C: a promising biomarker to evaluate renal function". *Revista Brasileira de Analises Clinicas*. 2017;49 (3).
60. Wei L, Ye X, Pei X, Wu J, Zhao W. Reference intervals for serum cystatin C and factors influencing cystatin C levels other than renal function in the elderly. *PLOS One*. 2014;9(1):e86066.
61. Yashiro M, Kamata T, Segawa H, Kadoya Y, Murakami T, Muso E. Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease. *Clin Exp Nephrol*. 2009;13(6):598–604.
62. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *N Engl J Med*. 2021;385(19):1737–49.
63. Nitta K, Hayashi T, Uchida K, Honda K, Tsukada M, Sekine S, et al. Serum cystatin C concentration as a marker of glomerular filtration rate in patients with various renal diseases. *Intern Med*. 2002;41(11):931–5.

64. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. *Nephron*. 2002;91(1):13–20
65. Vigil A, Condés E, Vigil L, Gallar P, Olié A, Ortega O, et al. Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease. *Int J Nephrol*. 2014;2014:127943.
66. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. *N Engl J Med*. 2005;352(20):2049–60.
67. Rachmah Q, Atmaka DR, Haryana NR, Daud ZAM. Predictors of chronic kidney disease among Indonesian adult population: Results from the 2018 Indonesia Basic Health Research. *F1000Res*. 2023;12:354.
68. Ma Y, Lin J, Xia P, Zheng H, Cheng X, Ji P, et al. Comparison of the profiles of patients defined by age-adapted and fixed threshold CKD criteria: a nationwide, cross-sectional study. *Clin Kidney J*. 2022;15(12):2312–21.
69. Hustrini NM, Susalit E, Lydia A, Marbun MBH, Syafiq M, Yassir, et al. The Etiology of Kidney Failure in Indonesia: A Multicenter Study in Tertiary-Care Centers in Jakarta. *Ann Glob Health*. 2023;89(1):36.
70. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLoS One*. 2016;11(7):e0158765.
71. Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a

- contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study. *The Lancet Regional Health - Europe*. 2022;20:100438.
72. Centers for Disease Control (CDC). Chronic Kidney Disease in The United States. U.S Department of Health and Human Service. 2023.
 73. Tanaka T, Maruyama S, Chishima N, Akiyama H, Shimamoto K, Inokuchi S, et al. Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study. *Sci Rep*. 2024;14(1):5172.
 74. Liu P, Quinn RR, Lam NN, Al-Wahsh H, Sood MM, Tangri N, et al. Progression and Regression of Chronic Kidney Disease by Age Among Adults in a Population-Based Cohort in Alberta, Canada. *JAMA Netw Open*. 2021;4(6):e2112828.
 75. Kampmann JD, Heaf JG, Mogensen CB, Mickley H, Wolff DL, Brandt F. Prevalence and incidence of chronic kidney disease stage 3–5 – results from KidDiCo. *BMC Nephrol*. 2023;24(1):17.
 76. Mahmood U, Healy HG, Kark A, Cameron A, Wang Z, Abeysekera R, et al. Spectrum (characteristics) of patients with chronic kidney disease (CKD) with increasing age in a major metropolitan renal service. *BMC Nephrol*. 2017;18(1):372.
 77. Ricardo AC, Yang W, Sha D, Appel LJ, Chen J, Krousel-Wood M, et al. Sex-Related Disparities in CKD Progression. *Journal of the American Society of Nephrology*. 2019;30(1):137–46.

78. Bikbov B, Perico N, Remuzzi G. Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. *Nephron*. 2018;139(4):313–8.
79. Neugarten J, Golestaneh L. Influence of Sex on the Progression of Chronic Kidney Disease. *Mayo Clin Proc*. 2019;94(7):1339–56.
80. Chang TJ, Zheng CM, Wu MY, Chen TT, Wu YC, Wu YL, et al. Relationship between body mass index and renal function deterioration among the Taiwanese chronic kidney disease population. *Sci Rep*. 2018;8(1):6908.
81. Yim HE, Yoo KH. Obesity and chronic kidney disease: prevalence, mechanism, and management. *Clin Exp Pediatr*. 2021;64(10):511–8.
82. IRR. (2020). 13th ANNUAL REPORT OF INDONESIAN RENAL REGISTRY 2020. Perhimpunan Nefrologi Indonesia.
83. Hawthorne G, Lightfoot CJ, Smith AC, Khunti K, Wilkinson TJ. Multimorbidity prevalence and patterns in chronic kidney disease: findings from an observational multicentre UK cohort study. *Int Urol Nephrol*. 2023;55(8):2047–57.
84. Hung CC, Yu PH, Niu SW, Kuo IC, Lee JJ, Shen FC, et al. Association between Body Mass Index and Renal Outcomes Modified by Chronic Kidney Disease and Anemia: The Obesity Paradox for Renal Outcomes. *J Clin Med*. 2022;11(10):2787.
85. Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP. Association of body mass index with outcomes in patients with CKD. *J Am Soc Nephrol*. 2014;25(9):2088–96.

86. Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. *Journal of the formosan Medical Association*. 2018;117(8): 662 –75.
87. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. *American Journal of Kidney Diseases*. 2019;74(1):120–31.
88. Yaxley J, Yaxley W. Obstructive uropathy – acute and chronic medical management. *World J Nephrol*. 2023;12(1):1–9.
89. Roni A., Eko N., Suwarsi. Overview of ureum and creatinin levels in hemodialysis patients with chronic kidney disease. *Jurnal laboratorium Medis*. 2020; 2 (1);1–3
90. Irendem K., Gladys I., Mayer F. Gambaran kadar ureum pada pasien penyakit ginjal kronik stadium 5 non dialisis. *Jurnal eBm*. 2016; 4(2); 1–4.
91. Ni Wayan, Luh Gede, Putu Nita Cahyawati. Hubungan Kadar Kreatinin dan Ureum dengan Derajat Anemia pada Pasien Penyakit Ginjal Kronik di RSUD Sanjiwani Gianyar. *Aesculapius Medical Journal*. 2023; (3); 74–80.
92. Bargnoux AS, Kuster N, Cavalier E, Piéroni L, Souweine JS, Delanaye P, et al. Serum creatinine: advantages and pitfalls. *J Lab Precis Med*. 2018;3:71–71.
93. Brennan AT, Kileel EM, Khoza S, Crowther NJ, Bor J, Fox MP, et al. Prevalence and progression of chronic kidney disease among adults undergoing creatinine testing in South African public healthcare facilities: a study leveraging data from South Africa's National Health Laboratory Service (NHLS). *BMJ Public Health*. 2024;2(1):e000799.

94. Rajayapandian K, Prasanthi Singaravel V, Natesan S. Study of Serum Uromodulin as A Biomarker of Kidney Function in Patients with CKD and to Identify Early Stages of Chronic Kidney Disease. *European Journal of Cardiovascular Medicine* [Internet]. 2024;14(3):76–83.
95. Thielemans R, Speeckaert R, Delrue C, De Bruyne S, Oyaert M, Speeckaert MM. Unveiling the Hidden Power of Uromodulin: A Promising Potential Biomarker for Kidney Diseases. *Diagnostics*. 2023;13(19):3077.
96. Scherberich JE, Gruber R, Nockher WA, Christensen EI, Schmitt H, Herbst V, et al. Serum uromodulin—a marker of kidney function and renal parenchymal integrity. *Nephrology Dialysis Transplantation*. 2018;33(2):284–95.
97. Tapper M, McGrowder DA, Dilworth L, Soyibo A. Cystatin C, Vitamin D and Thyroid Function Test Profile in Chronic Kidney Disease Patients. *Diseases*. 2021;9(1):5.
98. Woo KS, Choi JL, Kim BR, Kim JE, Han JY. Clinical Usefulness of Serum Cystatin C as a Marker of Renal Function. *Diabetes Metab J*. 2014;38(4):278.
99. Benoit SW, Ciccio EA, Devarajan P. Cystatin C as a biomarker of chronic kidney disease: latest developments. *Expert Rev Mol Diagn*. 2020 ;20(10):1019–26.
100. DSa J. Association Between Serum Cystatin C and Creatinine in Chronic Kidney Disease Subjects Attending a Tertiary Health Care Centre. *J Clin Diagn Res*. 2017;11(4):9–12.

101. Jurgen E.S., Rudolf G., Wolfgang A.N., Erik I.C., Hans S., Victor H., et al. Serum uromodulin- a marker of kidney function and renal parnechymal integrity. *Nephrology dialysis tranplantation*. 2018;33(2):284–95.
102. Soma A., Sreedhar S., Venkata P.R., Manoj Umare. Role of serum uromodulin as a biomarker of decline in renal function in chronic kidney disease. *Int J Med Pub Health*. 2024; 14 (2); 191–5.
103. Genov D., Kundurdgiev A., Ivanova I., Nikolova M., Pencheva V., Hristova M., et al. Role of serum uromodulin in the early diagnosis of chronic kidney disease. *Acta Medica Bulgarica*. 2021;48(1):1–4.
104. Shaimaa I., Eman M., Sahar S., Tarek M. Association of serum uromodulin with diabetic kidney disease : a systematic review and meta-analysis. *BMC Nephrology*. 2024; 25: 1–8.
105. Dumpatna R., Tristina N., Turbawaty D. K., Tjandrawati, A. Validity of Serum Uromodulin as Early Diagnosis Marker of Diabetic Nephropathy in T2DM. *Majalah Kedokteran Bandung*. 2021; 53(2): 107–13.
106. Sukanya S., Janice Dsa, Tirthal R., Srinidhi R., Roopa B. Serum cystatin c in chronic kidney disease: a case-control study. *Aviceena J Med Biochem*. 2021; 9 (2): 83–7.
107. Heru K., Achsanuddin H., Chairul M. Perbandingan cystatin c serum dan kreatinin serum untuk deteksi cedera ginjal akut pada pasien sepsis di ruang rawat intensif rumah sakit haji adam malik medan. *Majalah anastesi dan critical care*. 2014;32(1):34–9
108. Ahmed E.M., Rasha O.A., Ayman M., Walaa M.I. The utility of estimation of glomerular filtration rate by serum cystatin c as a predictor of diabetic kidney

disease in both type I and type II diabetic patients: a single center study. The Egyptian Journal of Internal Medicine. 2023; 64.

109. Vyankatesh T.A., Shilpa V.S., Assesment of serum cystatin c marker in patients of chronic kidney disease. Int J Pharm. 2023;79(2):113–5.
110. Tuan N.V., Linh P.H., Diep P.T., Minh N.T., Thuan H.Q., Lan T.P. The level of plasma cystatin c in patients with chronic kidney disease. Nephro-Urology Monthly. 2022;14(2): 1–4.

